Suggested remit - To appraise the clinical and cost effectiveness of pembrolizumab in combination with carboplatin and paclitaxel or nab-paclitaxel within its marketing authorisation for untreated metastatic squamous non-small-cell lung cancer.
Status In progress
Process STA 2018
ID number 1306

Provisional Schedule

Expected publication 04 July 2019

Project Team

Project lead Kate Moore

Email enquiries


Companies sponsors Merck Sharp & Dohme (pembrolizumab)
Others Department of Health and Social Care
  NHS East Lancashire CCG
  NHS England
  NHS Hartlepool and Stockton-on-Tees CCG
  Welsh Government
Patient carer groups Black Health Agency
  British Lung Foundation
  Cancer Black Care
  Cancer Equality
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  Roy Castle Lung Cancer Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  UK Lung Cancer Coalition
Professional groups Association of Cancer Physicians
  Association of Respiratory Nurse Specialists
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  National Lung Cancer Forum for Nurses
  Primary Care Respiratory Society UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society


Comparator companies Accord Healthcare (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel, vinorelbine)
  Celgene (paclitaxel)
  Dr Reddy’s Laboratories (docetaxel)
  Fresenius Kabi (paclitaxel)
  Hospira UK (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel)
  Lilly UK (gemcitabine)
  Medac GmbH (docetaxel, gemcitabine, paclitaxel, vinorelbine)
  Merck Sharp & Dohme (pembrolizumab)
  Pfizer (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel)
  Pierre Fabre (vinorelbine)
  Sun Pharma (carboplatin, gemcitabine)
  Sandoz (cisplatin)
  Sanofi (docetaxel)
  Seacross pharmaceuticals (docetaxel)
  Teva (carboplatin, cisplatin, docetaxel, paclitaxel)
General commentators All Wales Therapeutic and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Commercial Medicines Unit
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Lung Cancer Group
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
24 August 2018 Invitation to participate
18 July 2018 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab with carboplatin and paclitaxel for untreated squamous non-small-cell lung cancer. Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late August 2018.
22 May 2018 - 20 June 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
16 April 2018 Committee meeting: 1
28 September 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance